Emerging targets in cancer immunotherapy: beyond CTLA-4 and PD-1.
Assal, Amer
Emerging targets in cancer immunotherapy: beyond CTLA-4 and PD-1. [electronic resource] - Immunotherapy 2015 - 1169-86 p. digital
Publication Type: Journal Article; Meta-Analysis; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.; Review
1750-7448
10.2217/imt.15.78 doi
Animals
Antigens, CD--metabolism
Antineoplastic Combined Chemotherapy Protocols--therapeutic use
B7-H1 Antigen--antagonists & inhibitors
CTLA-4 Antigen--immunology
Clinical Trials as Topic
Humans
Immunotherapy
Molecular Targeted Therapy
Neoplasms--immunology
Programmed Cell Death 1 Receptor--immunology
Tumor Escape--drug effects
Tumor Necrosis Factor-alpha--antagonists & inhibitors
Lymphocyte Activation Gene 3 Protein
Emerging targets in cancer immunotherapy: beyond CTLA-4 and PD-1. [electronic resource] - Immunotherapy 2015 - 1169-86 p. digital
Publication Type: Journal Article; Meta-Analysis; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.; Review
1750-7448
10.2217/imt.15.78 doi
Animals
Antigens, CD--metabolism
Antineoplastic Combined Chemotherapy Protocols--therapeutic use
B7-H1 Antigen--antagonists & inhibitors
CTLA-4 Antigen--immunology
Clinical Trials as Topic
Humans
Immunotherapy
Molecular Targeted Therapy
Neoplasms--immunology
Programmed Cell Death 1 Receptor--immunology
Tumor Escape--drug effects
Tumor Necrosis Factor-alpha--antagonists & inhibitors
Lymphocyte Activation Gene 3 Protein